1. New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms.
- Author
-
Zhang Y, Zhao Y, Liu Y, Zhang M, and Zhang J
- Subjects
- Humans, Signal Transduction genetics, DNA Damage genetics, Janus Kinase Inhibitors therapeutic use, Janus Kinase Inhibitors pharmacology, Janus Kinase 2 genetics, Myeloproliferative Disorders genetics, Myeloproliferative Disorders drug therapy, Myeloproliferative Disorders pathology, Mutation
- Abstract
The JAK2 V617F mutation is the most common driver gene in myeloproliferative neoplasm (MPN), which means that the JAK/STAT signaling pathway is persistently activated independent of cytokines, and plays an important part in the onset and development of MPN. The JAK inhibitors, although widely used in the clinical practice, are unable to eradicate MPN. Therefore, the unavoidable long-term treatment poses a serious burden for patients with MPN. It is established that the JAK2 V617F mutation, in addition its role in the JAK/STAT pathway, can promote cell proliferation, differentiation, anti-apoptosis, DNA damage accumulation, and other key biologic processes through multiple pathways. Other than that, the JAK2 V617F mutation affects the cardiovascular system through multiple mechanisms. Although JAK inhibitors cannot eradicate MPN cells, the combined use of JAK inhibitors and other drugs may have surprising effects. This requires an in-depth understanding of the mechanism of action of the JAK2 V617F mutation. In this review, the authors explored the role of the JAK2 V617F mutation in MPN from multiple aspects, including the mechanisms of non-JAK/STAT pathways, the regulation of cellular methylation, the induction of cellular DNA damage accumulation, and effects on the cardiovascular system, with the objective of providing valuable insights into multidrug combination therapy for MPN., (© 2024 American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF